Beating AI News Flash: Isomorphic Labs, the AI drug discovery company under Google's parent company Alphabet, has announced the completion of a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital, with participation from a16z and other institutions, while Alphabet continues to invest.
Isomorphic Labs had just completed a $2.1 billion Series B funding round in May of this year. In just half a year, the two rounds of funding totaled $7.1 billion.
The company is led by Nobel laureate and Google DeepMind co-founder Demis Hassabis, and its core technology is the AI drug design system IsoDDE. It uses AI to predict molecular structures, interactions, and drug properties, helping researchers design, screen, and optimize new drugs.
Isomorphic Labs stated that more than 20 drug development projects are currently underway, with positive preclinical results achieved in cancer and immune disease areas, but no self-developed drugs have yet entered human trials. Hassabis predicted in January of this year that the first batch of drugs would begin clinical trials before the end of 2026.
However, in this interview with Bloomberg, he did not update that timeline, only stating that regulatory filings are still proceeding as planned, with more news to come in 2027. This round of funding will also be used to expand the scale of drug development and prepare for subsequent clinical trials.
